A new type of antibiotic can effectively treat an antibiotic-resistant infection by disarming instead of killing the bacteria that cause it. Researchers report their findings in the October 2 issue of mBio®, the online open-access journal of the American Society for Microbiology.
“Traditionally, people have tried to find antibiotics that rapidly kill bacteria. But we found a new class of antibiotics which has no ability to kill Acinetobacter that can still protect, not by killing the bug, but by completely preventing it from turning on host inflammation,” says Brad Spellberg of the UCLA Medical Center and David Geffen School of Medicine, a researcher on the study.
[Lily] Yeh is the founder of — and force behind — Barefoot Artists, an organization that revitalizes neighborhoods around the globe through the transformative power of art. In Palestine, that meant working with villagers to create a wall mural that Yeh calls “The Palestinian Tree of Life.” In China, it meant transforming a once imposing, prison-like school into a bright and brilliant place for learning. In Rwanda, it meant helping people heal the still-raw wounds left from that country’s genocide with a memorial to the lost.
In each of the locations, Barefoot Artists collaborates with locals, joining with them to create something beautiful or soothing or enlightening. As Yeh sees it, she is igniting the light of creativity that rests in all people.
The researchers, led by Marc Ostermeier, a Johns Hopkins chemical and biomolecular engineering professor in the Whiting School of Engineering, showed that these switches, working from inside the cells, can activate a powerful cell-killing drug when the device detects a marker linked to cancer. The goal, the scientists said, is to deploy a new type of weapon that causes cancer cells to self-destruct while sparing healthy tissue.
Promising results raise hope for cancer breakthrough: T cells could be tweaked to kill a range of cancers.
In a potential breakthrough in cancer research, scientists at the University of Pennsylvania have genetically engineered patients’ T cells — a type of white blood cell — to attack cancer cells in advanced cases of a common type of leukemia.
Two of the three patients who received doses of the designer T cells in a clinical trial have remained cancer-free for more than a year, the researchers said.
When the places and animals we love are damaged or endangered, we hurt too.
But by going to these places, telling our stories, and making simple acts of beauty, we heal the land and claim our place in a world we create with beauty, meaning, and even joy
In a matter of hours, mind-altering substances may induce profound psychological realignments that can take decades to achieve on a therapist’s couch.